1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow Pouya Azar: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Methadone Rapid Restart Methadone - Opioid Use Disorder | Phase 4 | Not yet recruiting | Pouya Azar | 25 | 2026-05-01 | 2026-04-22 |
| Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), Buprenorphine extended-release injection (300 mg/1.5 mL) - Opioid Use Disorder | Phase 4 | Recruiting | Pouya Azar | 12 | 2026-04-29 | 2026-05-01 |
| Symptom-inhibited Fentanyl Induction Fentanyl, Methadone, Slow-release oral morphine - Opioid Use Disorder | Phase 4 | Completed | Pouya Azar | 48 | 2024-01-29 | 2026-03-16 |
Methadone (2) · Buprenorphine (1) · Buprenorphine, Naloxone Drug Combination (1) · Fentanyl (1) · Morphine (1) · Naloxone (1) · Sublocade (1)
Canada (3)